| Market Capitalization (Millions $) |
1 |
| Shares
Outstanding (Millions) |
2 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-4 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Bone Biologics Corporation
Bone Biologics Corporation is a biotechnology company that specializes in the development of innovative products for bone regeneration and tissue engineering. The company focuses on the commercialization of its proprietary technology platform, called the Nell-1 protein, which has shown great potential in stimulating bone growth and healing.
Bone Biologics aims to address the significant unmet medical need for effective treatments for bone fractures, spinal fusion, and other bone-related conditions. Their goal is to improve patient outcomes and quality of life by providing novel and advanced therapies that accelerate the body's natural healing process.
The company's flagship product, called Nell-1 Osteoinductive Biological Implant, is designed to promote bone regeneration in spinal fusion procedures. It has demonstrated impressive results in preclinical and clinical studies, showing superior bone growth and quality compared to existing treatments.
Bone Biologics Corporation is committed to advancing the field of regenerative medicine and revolutionizing the way bone injuries and diseases are treated. They continue to invest in research and development to expand their product pipeline and address additional applications in bone healing and regeneration.
Company Address: 2 Burlington Woods Drive Burlington 1803 MA
Company Phone Number: 552-4452 Stock Exchange / Ticker: NASDAQ BBLG
|
1.23% 